Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 17 INDUSTRY 6 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrent Squamous Cell Lung Carcinoma 3 Prostatic Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Solid Malignancies 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Cancer Metastatic 1 Esophageal Neoplasms 1 Colorectal Cancer Metastatic 1 Cholangiocarcinoma 1 Carcinoma, Hepatocellular 1 Advanced Rare Tumours 1

Interventions

Paclitaxel 27 Carboplatin 23 Cisplatin 16 Topotecan 8 Taxes 8 Docetaxel 7 Gemcitabine 6 Filgrastim 5 Etoposide 4 Doxorubicin 4 Cyclophosphamide 4 Psychiatric Rehabilitation 3 Ifosfamide 3 Chemotherapy, Adjuvant 3 rubitecan 2 pegfilgrastim 2 paclitaxel poliglumex 2 liposomal doxorubicin 2 Trabectedin 2 Surgical Procedures, Operative 2 Polymerase Chain Reaction 2 Peripheral Blood Stem Cell Transplantation 2 Irinotecan 2 GEN-1 2 Fenretinide 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Celecoxib 2 Bevacizumab 2 Amifostine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Ovarian Neoplasms × durvalumab × Clear all

NCT04918186 2026-05-12

IPROC

Canadian Cancer Trials Group

Phase 2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡